Comparative Pharmacology
Head-to-head clinical analysis: SAFYRAL versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SAFYRAL versus STILPHOSTROL.
SAFYRAL vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Safyral is a combination of ethinyl estradiol and drospirenone. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, preventing ovulation. Drospirenone is a progestin with anti-mineralocorticoid activity, which may reduce fluid retention, and anti-androgenic activity, which may improve acne. It also increases cervical mucus viscosity, impeding sperm penetration.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
One tablet (drospirenone 3 mg/ethinyl estradiol 0.03 mg) orally once daily for 24 days, followed by 4 days of placebo.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
16.3 hours (range 12-21 hours) for drospirenone; 32.5 hours (range 24-42 hours) for ethinyl estradiol (EE); clinical context: steady-state achieved after 10 days for drospirenone, 7 days for EE
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Urine (40% as metabolites, 20% unchanged; fecal 30% as metabolites; biliary excretion contributes to enterohepatic circulation, prolonging elimination)
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category C
Category C
Oral Contraceptive Progestin/Estrogen
Estrogen